{"filings":[{"id":528956,"accession_number":"0001437749-26-017809","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-05-19T21:04:04+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax prices $3M private placement offering at $1.4799 per unit with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3M; net proceeds ~$2.7M after placement agent fees and expenses.","Issued 2,027,027 pre-funded warrants ($0.0001 exercise) and 4,054,054 common warrants at $1.48 exercise; Series A (5yr), Series B (18mo).","Offering closed May 19, 2026; net proceeds used for working capital and general corporate purposes.","Company agreed to file resale registration statement with SEC for shares underlying the warrants.","A.G.P./Alliance Global Partners acted as sole placement agent; received 7% cash fee plus expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443238,"accession_number":"0001437749-26-017070","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-05-14T20:23:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).","Cash $1.3M at March 31, 2026, down from $3.1M at Dec 31, 2025.","Phase 3 immunobridging study for GEO-MVA (mpox/smallpox) planned under EMA-aligned expedited pathway; enrollment ~500.","Completed cGMP manufacturing and fill/finish; CRO selected for trial initiation.","Exclusive license from Emory for Gedeptin in combination with immune checkpoint inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99122,"accession_number":"0001437749-26-015613","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GeoVax raises ~$595k via warrant inducement; issues new warrants for 1M shares at $1.65","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercise warrants for 501,144 shares; gross proceeds ~$595k before fees.","New warrants issued to purchase up to 1,002,288 shares at $1.65, exercisable after shareholder approval.","Closing expected May 8, 2026; proceeds for working capital and general corporate purposes.","New warrants issued in private placement under Regulation D; unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99121,"accession_number":"0001437749-26-012435","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.","Cash $3.1M at Dec 31, 2025; R&D expenses $18.1M (down from $23.7M); BARDA contract terminated Apr 2025.","GEO-MVA Phase 3 trial to start H2 2026; EMA supports streamlined development without Phase 1/2.","GEO-CM04S1 COVID vaccine Phase 2 data in 2026; Gedeptin oncology Phase 2 planned for 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114960,"accession_number":"0001437749-26-010733","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GeoVax raises ~$863k via warrant exercise inducement, issues new warrants for 1.27M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holders exercise 634,658 shares at reduced $1.36/share, gross proceeds ~$863k.","GeoVax issues new warrants to purchase up to 1,269,316 shares at $1.36, exercisable after stockholder approval.","Net proceeds to be used for working capital and general corporate purposes.","Closing expected April 1, 2026; A.G.P./Alliance Global Partners receives 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114959,"accession_number":"0001437749-26-004392","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$1M gross in registered direct offering priced at $2.31/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 432,902 shares (or pre-funded warrants) at $2.31/share; net proceeds ~$865,000.","Concurrent private placement of Series A-1 and A-2 warrants for up to 432,902 shares each, exercisable at $2.31 after shareholder approval.","Existing warrants for 236,000 shares amended: exercise price reduced from $4.35 to $2.31, subject to shareholder approval.","Proceeds to fund R&D, manufacturing, clinical studies, and working capital.","H.C. Wainwright acted as sole placement agent; closing occurred February 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114958,"accession_number":"0001437749-26-001113","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"GeoVax Labs effects 1-for-25 reverse stock split effective January 9, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each 25 shares of common stock automatically combined into 1 share; no fractional shares issued.","Percentage ownership and proportional voting power unchanged except rounding adjustments.","Certificate of Amendment filed January 9, 2026; new stock certificate form adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131350,"accession_number":"0001437749-25-038547","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$3.2M in public offering of 13.2M units at $0.245/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 13,244,896 common units at $0.245/unit, each consisting of one share plus warrants for two shares.","Gross proceeds ~$3.2M; net proceeds ~$2.9M after placement agent fees and offering expenses.","Warrants exercisable immediately at $0.245/share, expire 5 years from issuance.","Roth Capital Partners acted as exclusive placement agent; closing on December 22, 2025.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131349,"accession_number":"0001437749-25-036447","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"GeoVax stockholders approve reverse stock split and warrant share issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split authorized at ratio between 1:10 and 1:25, with 11.85M votes for and 2.16M against.","Issuance of up to 11,904,768 shares upon exercise of September 2025 warrants approved (5.81M for, 0.95M against).","Record date September 30, 2025; 29.71M shares outstanding; 14.13M proxies cast.","Board retains discretion to determine final split ratio and timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131348,"accession_number":"0001437749-25-034903","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.","Revenue fell to $0 as BARDA terminated Project NextGen contract for convenience in April 2025, compared to $2.8M in Q3 2024.","Cash $5.0M at Sep 30, 2025, down from $5.5M at Dec 31, 2024; burn rate continues.","GEO-MVA accelerated amid global Mpox emergency; EMA supports streamlined regulatory pathway.","GEO-CM04S1 met primary endpoint in CLL trial; Gedeptin expanding into new solid tumor indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2489145.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147928,"accession_number":"0001437749-25-030125","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$2.5M in registered direct offering; issues shares and warrants at $0.63","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,968,256 shares sold at $0.63 each with warrants to buy 11,904,768 shares at $0.63.","Gross proceeds ~$2.5M, net ~$2.325M after 7% placement agent fees.","Warrants exercisable only upon shareholder approval; expire 5 years from approval.","Roth Capital Partners acted as sole placement agent for the offering.","Proceeds to advance immunotherapies and vaccines pipeline including R&D and clinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147927,"accession_number":"0001437749-25-024389","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"GeoVax receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified GeoVax on July 31, 2025, that closing bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until January 27, 2026, to regain compliance with Bid Price Requirement.","Compliance can be achieved if closing bid price is at least $1.00 for a minimum of 10 consecutive business days.","If not compliant by deadline, GeoVax may qualify for an additional 180-day period by meeting other listing standards.","Stock continues trading on Nasdaq under symbol GOVX; company may consider a reverse stock split to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147926,"accession_number":"0001437749-25-023689","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax Q2 net loss $5.4M; cash $3.1M; BARDA contract terminated; GEO-MVA gets EU guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.37M ($0.35/share) vs $5.06M ($1.99/share) in Q2 2024; per-share loss down on share dilution.","Revenue from BARDA/RRPV contract $852k; BARDA terminated contract for convenience in Q2.","Cash $3.09M at June 30; completed July 2025 public offering netting ~$5.6M.","GEO-MVA received favorable EMA guidance allowing single Phase 3 immuno-bridging trial; trial expected 2H 2026.","GEO-CM04S1 showed superior T-cell responses vs mRNA in CLL; mRNA arm failed endpoint, enrollment restricted to GEO-CM04S1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2489145.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147925,"accession_number":"0001437749-25-021990","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$6M in public offering of 9.2M units at $0.65/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 9,235,000 units at $0.65/unit, each unit = 1 share + warrant to buy 2 shares.","Gross proceeds ~$6M; net proceeds ~$5.58M after fees and expenses.","Warrants exercisable immediately at $0.65, expire in 5 years, with 9.99% ownership blocker.","Proceeds to be used for working capital and general corporate purposes.","Offering closed July 2, 2025; Roth Capital Partners acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166647,"accession_number":"0001437749-25-019563","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GeoVax shareholders elect all seven directors, approve 2025 stock plan and warrant issuance at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; votes for ranged from 1,654,889 to 1,834,828, with 4,368,295 broker non-votes.","2025 Stock Incentive Plan approved: 1,548,171 for, 393,514 against, 63,263 abstain (4,368,295 broker non-votes).","Warrant exercise proposal (up to 3,435,115 shares) approved: 1,593,306 for, 376,141 against, 35,504 abstain.","Ratification of Wipfli LLP as auditor for FY2025 passed: 6,102,027 for, 231,866 against, 39,350 abstain; no broker non-votes.","Total shares voted: 6,373,243 out of 13,839,478 outstanding as of April 7, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166646,"accession_number":"0001437749-25-014147","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).","Cash $7.4M at Mar 31, 2025, up from $5.5M at Dec 31, 2024.","BARDA Project NextGen award terminated unexpectedly; GEO-CM04S1 COVID vaccine continues.","Healthy adult booster data for GEO-CM04S1 expected Q2 2025; GEO-MVA trial starts H2 2025.","Gedeptin advancing to Phase 2 for recurrent head/neck cancer with checkpoint inhibitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1636863.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166645,"accession_number":"0001437749-25-011926","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.","Contract covered Phase 2b clinical trial of GEO-CM04S1 COVID-19 vaccine; terminated for convenience to the government.","No financial details of termination or potential wind-down costs were disclosed in the filing.","GeoVax common stock (GOVX) and warrants (GOVXW) trade on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184065,"accession_number":"0001437749-25-009859","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).","Cash $5.5M at Dec 31, 2024, down from $6.5M; R&D expense $23.7M (up from $20.7M) on trial manufacturing.","BARDA $400M award supports 10,000-patient Phase 2b trial of GEO-CM04S1; manufacturing and sites confirmed.","DSMB cleared experimental arm of Phase 2 CLL trial after mRNA control arm failed primary endpoint.","Phase 2 booster data for GEO-CM04S1 in healthy adults expected H1 2025; GEO-MVA clinical eval expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184064,"accession_number":"0001437749-25-009141","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"GeoVax Labs raises $4.5M in registered direct offering, amends existing warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,435,115 shares or equivalents and common warrants at $1.31/unit, gross proceeds ~$4.5M.","Net proceeds of ~$4.1M after fees; for working capital and general corporate purposes.","Existing warrants for 2,675,610 shares amended: exercise price cut to $1.31, term extended to 5 years from closing.","Common warrants exercisable only after shareholder approval; expire 5 years from that approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184063,"accession_number":"0001437749-25-001556","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GeoVax shareholders approve issuance of up to 3.78M shares upon warrant exercises in two private placements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May 2024 warrant exercise proposal approved: 1,294,141 for, 287,649 against, 93,544 abstain.","July 2024 warrant exercise proposal approved: 1,306,150 for, 275,705 against, 93,479 abstain.","Total shares issuable if both warrants exercised: up to 1,605,688 (May) + 2,170,000 (July) = 3,775,688 shares.","Only 33.4% of outstanding shares (1,675,334 of 5,013,700) were voted at the reconvened special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200670,"accession_number":"0001437749-24-037842","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GeoVax Labs adjourns special meeting due to lack of quorum; reconvenes Jan 22, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Only 32.2% of shares voted; quorum not achieved at Dec 18, 2024 reconvened meeting.","Meeting originally convened Sep 17, 2024, adjourned; reconvened Dec 18, again adjourned to Jan 22, 2025.","Proxies previously submitted remain valid unless revoked; no changes to proposals from August 2024 proxy.","Polls remain open to provide additional time for stockholders to vote on all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200669,"accession_number":"0001437749-24-035609","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GeoVax Labs regains Nasdaq compliance with $8.5M stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 18, 2024 confirming compliance with Listing Rule 5550(b)(1) based on $8,503,876 stockholders' equity as of Sep 30, 2024.","Previously received extension until Nov 19, 2024 to cure deficiency; matter now closed.","Company had been notified of non-compliance on May 23, 2024 due to insufficient stockholders' equity.","Maintains listing on Nasdaq Capital Market; common stock trades under GOVX and warrants under GOVXW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200668,"accession_number":"0001437749-24-034910","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).","Revenue of $2.8M from BARDA/RRPV Project NextGen award (no revenue in prior year period).","Cash $8.6M at Sep 30, 2024, vs $6.5M at Dec 31, 2023.","BARDA Phase 2b trial of GEO-CM04S1 (10,000 patients) preparing for activation; sites confirmed.","Special Meeting adjourned without business due to lack of quorum (30.4% proxy turnout); reconvened Dec 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3090161.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200667,"accession_number":"0001437749-24-031364","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GeoVax special meeting adjourned for lack of quorum; reconvenes Nov 12, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting reconvened Oct 16, 2024, adjourned without business; only 28.6% of shares represented.","Meeting postponed to Nov 12, 2024, at 8:30 a.m. ET to allow more time for voting.","Proposals unchanged from proxy filed Aug 1, 2024; previously submitted proxies remain valid.","Stockholders who already voted need not take any action; proxies may be revoked."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200666,"accession_number":"0001437749-24-031266","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GeoVax Labs boosts ATM equity offering capacity from $4.5M to $30M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price under Sales Agreement with A.G.P./Alliance Global Partners increased from $4,486,846 to $30,000,000.","Sales Agreement originally dated September 25, 2024; amendment filed October 15, 2024.","Increase allows up to $30M in common stock sales via at-the-market offering.","Legal opinion on share legality filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200665,"accession_number":"0001437749-24-030377","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GeoVax Labs Special Meeting adjourned for lack of quorum; reconvenes Oct 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting reconvened Oct 1, 2024, adjourned without business due to insufficient quorum.","Only ~27% of outstanding common shares represented by proxies at adjournment.","Meeting reconvened on Oct 16, 2024 at 8:30 a.m. ET; polls remain open for voting.","No changes to proposals from proxy statement filed Aug 1, 2024.","Proxies previously submitted will be voted unless revoked; no action needed from prior voters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216681,"accession_number":"0001437749-24-029998","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GeoVax enters ATM agreement with A.G.P. to sell up to $4.5M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering of up to $4,486,846 in common stock via A.G.P. as agent; commission 3% of gross proceeds.","Company may sell shares from time to time at market prices; no obligation to sell any shares.","A.G.P. reimbursed up to $50,000 upfront and $5,000 per quarter for due diligence.","Sales under existing effective S-3 registration statement (File No. 333-277585)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216680,"accession_number":"0001437749-24-029372","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GeoVax Labs adjourns special meeting for lack of quorum; reconvenes Oct 1, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Sept 17, 2024 adjourned with no business conducted due to lack of quorum.","Only ~24% of outstanding common stock shares were represented by proxy at adjournment.","Meeting reconvenes Oct 1, 2024 at 8:30 a.m. ET; polls remain open for additional voting.","No changes made to the proposals described in the Aug 1, 2024 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216679,"accession_number":"0001437749-24-028138","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$5.0M in registered direct offering at $5.125/share with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 837,500 common shares at $5.125/share and 138,110 pre-funded warrants at $5.12499, exercise price $0.0001.","Concurrent private placement issued 975,610 common warrants at $5.00/share, exercisable immediately, 5-year term.","Gross proceeds ~$5.0M; net proceeds ~$4.6M after placement agent fees and expenses.","Roth Capital Partners served as exclusive placement agent; offering closed August 30, 2024.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216678,"accession_number":"0001437749-24-027483","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$8.5M in registered direct offering of 1.7M shares at $5.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $8.5M; net proceeds ~$7.855M after fees and expenses.","Offering: 1,360,731 common shares and 339,269 pre-funded warrants at $5.00/$4.99999 per unit.","Concurrent private placement of warrants to buy 1.7M common shares, exercisable at $5.00 for five years.","Net proceeds to be used for working capital and general corporate purposes.","Roth Capital Partners as placement agent; offering closed August 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216677,"accession_number":"0001437749-24-025175","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.","BARDA Project NextGen award for GEO-CM04S1 Phase 2b trial; total value $367-388M incl. Allucent.","Cash $1.56M at June 30, 2024, down from $6.45M at Dec 31, 2023.","Gedeptin advanced to expanded Phase 2 trial for head and neck cancer; activation H1 2025.","Commercial manufacturing platform for GEO-CM04S1 established with Oxford Biomedica."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":300677.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216676,"accession_number":"0001437749-24-022656","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$3.1M gross in offering of stock, pre-funded and common warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,085,000 shares (or equivalents) at $2.86; pre-funded warrants for 626,368 shares and common warrants for 2,170,000 shares.","Net proceeds ~$2.836M after fees; use for working capital and general corporate purposes.","Warrants exercisable post-stockholder approval at $2.86 per share, five-year term; lock-up provisions for 38 days.","Closing expected July 12, 2024; Roth Capital Partners acted as placement agent with 7.0% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236351,"accession_number":"0001437749-24-020958","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["3.01","3.03","9.01"],"status":"ready","headline":"GeoVax receives Nasdaq non-compliance notice but regains compliance via warrant amendment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company issued 802,844 shares and warrants in $1.3M private placement at $1.68/unit, triggering Nasdaq Rule 5635(d).","Nasdaq notified GeoVax on June 20, 2024, of failure to obtain prior shareholder approval for >20% issuance below minimum price.","On June 14, 2024, GeoVax amended warrants via Side Letter to require stockholder approval, eliminating deficiency.","Nasdaq determined compliance regained; matter closed; listing of GOVX and GOVXW unaffected.","Warrant exercise now contingent on shareholder approval; no value attributed to warrants in pricing calculation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236350,"accession_number":"0001437749-24-020615","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.","BARDA separately commits ~$343M from Project NextGen for a CRO to execute the 10,000-participant Phase 2b study.","Phase 2b double-blinded trial will compare GeoVax's GEO-CM04S1 against an FDA-approved mRNA COVID-19 vaccine.","Study is part of HHS Project NextGen, a $5B initiative for next-generation COVID-19 vaccines and therapeutics.","GeoVax's dual-antigen vaccine candidate aims to induce durable antibody and T-cell immunity against variants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236349,"accession_number":"0001437749-24-018321","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GeoVax Labs receives Nasdaq delisting notice for failing $2.5M equity minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received May 23, 2024; stockholders' equity as of March 31, 2024 below $2.5M requirement.","Company has until July 8, 2024 to submit a plan to regain compliance with Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension from notice date.","Trading under symbol GOVX continues for now; delisting risk remains if plan rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236348,"accession_number":"0001437749-24-018144","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"GeoVax shareholders approve all proposals at annual meeting; quorum reduced to 33 1/3%","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with between 440,096 and 517,969 votes for.","Proposal to approve issuance of up to 1,408,998 shares upon warrant exercise passed (480,421 for vs 69,206 against).","Bylaw amendment reducing stockholder quorum from majority to 33 1/3% approved (489,102 for, 61,758 against).","Ratification of Wipfli LLP as independent auditor for FY 2024 approved (1,090,966 for, 53,665 against).","Proxies represented 1,177,811 of 2,308,309 outstanding shares as of March 25, 2024 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236347,"accession_number":"0001437749-24-017865","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeoVax raises ~$1.3M in registered direct offering and warrant placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 220,000 shares and 582,844 pre-funded warrants at $1.68/share; gross proceeds ~$1.3M.","Concurrent private placement: warrants to purchase up to 1,605,688 shares at $1.68, 5-year term.","Net proceeds ~$1.18M for working capital and general corporate purposes.","Roth Capital Partners acted as placement agent with a 7% cash fee.","Offering closed on May 21, 2024; 90-day lock-up on further equity issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236346,"accession_number":"0001437749-24-017040","cik":832489,"company_name":"GeoVax Labs, Inc.","ticker":"GOVX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.","Cash balance fell to $768,859 from $6.45M at Dec 31, 2023, a decline of ~$5.7M.","R&D expenses rose to $4.43M from $2.82M, driven by manufacturing costs for clinical trials.","Phase 2 GEO-CM04S1 COVID vaccine booster trial showed statistically significant neutralizing antibody increases against multiple variants.","Gedeptin Phase 1/2 for head and neck cancer completed enrollment; expected to complete Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9273603.893982807,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}